Peregrine Announces Participation at Upcoming Investor Conferences in March
(firmenpresse) - TUSTIN, CA -- (Marketwire) -- 02/27/12 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced that Steven King, president and CEO, will present at the following two investor conferences in March:
32nd Cowen Health Care Conference on Monday, March 5, 2012, at 4:10pm Eastern Time at the Marriott Copley Hotel in Boston
24th Annual ROTH Conference on Monday, March 12, 2012, at 11:00am Pacific Time at the Ritz Carlton Hotel in Laguna Nigel
Peregrine's presentation at the 24th Annual Roth Conference will be webcast live and available for replay until April 2, 2012 at:
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious disease with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at .
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.02.2012 - 21:00 Uhr
Sprache: Deutsch
News-ID 119049
Anzahl Zeichen: 0
contact information:
Town:
TUSTIN, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Peregrine Announces Participation at Upcoming Investor Conferences in March"
steht unter der journalistisch-redaktionellen Verantwortung von
Peregrine Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
